Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
277,630 results
  • Clinical manifestations and management of fatty acid oxidation disorders. [Review]
    Rev Endocr Metab Disord. 2020 Jul 11 [Online ahead of print]Merritt JL, MacLeod E, … Hainline B
  • Fatty acid oxidation disorders (FAOD) are a group of rare, autosomal recessive, metabolic disorders caused by variants of the genes for the enzymes and proteins involved in the transport and metabolism of fatty acids in the mitochondria. Those affected by FAOD are unable to convert fatty acids into tricarboxylic acid cycle intermediates such as acetyl-coenzyme A, resulting in decreased adenosine …
  • Purine Metabolism in Platelets and Heart Cells of Hyperlipidemic Rats. [Journal Article]
    Cardiovasc Drugs Ther. 2020 Jul 11 [Online ahead of print]Manzoni AG, Passos DF, … Leal DBR
  • CONCLUSIONS: Together, these findings are indicative of an increased risk of developing cardiovascular diseases in hyperlipidemic rats. The pretreatments with antioxidants reverted some of the changes prompted by hyperlipidemia preventing detrimental changes in the cells and tissues. Graphical Abstract.
  • Busulfan Pharmacokinetics in ADA SCID Gene Therapy. [Journal Article]
    Biol Blood Marrow Transplant. 2020 Jul 09 [Online ahead of print]Bradford KL, Liu S, … Kohn DB
  • The pharmacokinetics of low dose busulfan (BU) were investigated as a non-myeloablative conditioning regimen for autologous gene therapy (GT) in pediatric subjects with adenosine deaminase-deficient severe combined immunodeficiency (ADA SCID). In three successive clinical trials, which included either γ-retroviral (γ-RV) or lentiviral (LV) vectors, subjects were conditioned with BU using differen…
  • Design and Pharmacological Profile of a Novel Covalent Partial Agonist for the Adenosine A1 Receptor. [Journal Article]
    Biochem Pharmacol. 2020 Jul 09 [Online ahead of print]Yang X, Dilweg MA, … IJzerman AP
  • Partial agonists for G protein-coupled receptors (GPCRs) provide opportunities for novel pharmacotherapies with enhanced on-target safety compared to full agonists. For the human adenosine A1 receptor (hA1AR) this has led to the discovery of capadenoson, which has been in phase IIa clinical trials for heart failure. Accordingly, the design and profiling of novel hA1AR partial agonists has become …
  • Pharmacokinetic functions of human induced pluripotent stem cell-derived small intestinal epithelial cells. [Journal Article]
    Drug Metab Pharmacokinet. 2020 May 16 [Online ahead of print]Kabeya T, Mima S, … Matsunaga T
  • To develop a novel intestinal drug absorption system using intestinal epithelial cells derived from human induced pluripotent stem (iPS) cells, the cells must possess sufficient pharmacokinetic functions. However, the CYP3A4/5 activities of human iPS cell-derived small intestinal epithelial cells prepared using conventional differentiation methods is low. Further, studies of the CYP3A4/5 activiti…
  • Adenosine deaminase 2 activity negatively correlates with age during childhood. [Journal Article]
    Pediatr Rheumatol Online J. 2020 Jul 10; 18(1):54.Bowers SM, Gibson KM, … Brown KL
  • CONCLUSIONS: We observed that ADA2 enzyme activity, but not ADA2 protein concentration, negatively correlates with age in a cohort of children and adolescents. Our findings stress the importance of appropriate age-matched controls for assessing ADA2 enzyme activity in the clinical setting.
  • Artificial Organelles for Energy Regeneration. [Review]
    Adv Biosyst. 2019 Jun; 3(6):e1800323.Otrin L, Kleineberg C, … Vidaković-Koch T
  • One of the critical steps in sustaining life-mimicking processes in synthetic cells is energy, i.e., adenosine triphosphate (ATP) regeneration. Previous studies have shown that the simple addition of ATP or ATP regeneration systems, which do not regenerate ATP directly from ADP and Pi , have no or only limited success due to accumulation of ATP hydrolysis products. In general, ATP regeneration ca…
  • The role of the CD39-CD73-adenosine pathway in liver disease. [Review]
    J Cell Physiol. 2020 Jul 10 [Online ahead of print]Wang S, Gao S, … Lv X
  • Extracellular adenosine triphosphate (ATP) is a danger signal released by dying and damaged cells, and it functions as an immunostimulatory signal that promotes inflammation. The ectonucleotidases CD39/ectonucleoside triphosphate diphosphohydrolase-1 and CD73/ecto-5'-nucleotidase are cell-surface enzymes that breakdown extracellular ATP into adenosine. This drives a shift from an ATP-driven proin…
  • Real-time in vivo imaging of extracellular ATP in the brain with a hybrid-type fluorescent sensor. [Journal Article]
    Elife. 2020 Jul 10; 9Kitajima N, Takikawa K, … Hirose K
  • Adenosine 5' triphosphate (ATP) is a ubiquitous extracellular signaling messenger. Here, we describe a method for in-vivo imaging of extracellular ATP with high spatiotemporal resolution. We prepared a comprehensive set of cysteine-substitution mutants of ATP-binding protein, Bacillus FoF1-ATP synthase e subunit, labeled with small-molecule fluorophores at the introduced cysteine residue. Screeni…
  • Deletion of TRPV4 enhances in vitro wound healing of murine esophageal keratinocytes. [Journal Article]
    Sci Rep. 2020 Jul 09; 10(1):11349.Boudaka A, Saito CT, Tominaga M
  • Transient receptor potential vanilloid 4 (TRPV4) is a non-selective cation channel that is widely expressed in different body tissues and plays several physiological roles. This channel is highly expressed in esophageal keratinocytes where its activation mediates ATP release. However, whether TRPV4 has a role in wound healing of esophageal keratinocytes is unclear. In this study, we demonstrated …
  • StatPearls: Phosphodiesterase Inhibitors [BOOK]
    . StatPearls Publishing: Treasure Island (FL) Padda Inderbir S. IS University of Washington Tripp Jayson J CUSOM/Cape Fear Valley Health Center BOOK
  • Phosphodiesterase inhibitors(PDE inhibitors) are a class of agents acting on specific phosphodiesterase enzymes in target cells and are FDA approved for the management of chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, psoriasis, psoriatic arthritis, and atopic dermatitis.[1][2] Phosphodiesterase enzymes' essential role serves to separate the phosphat…
New Search Next